The Pharmacokinetic and Pharmacodynamic Properties of Biphasic Insulin Aspart 70 (BIAsp 70) are Significantly Different from those of Biphasic Insulin Aspart 30 (BIAsp 30)

Abstract

Aims: To evaluate the pharmacokinetic and pharmacodynamic properties of two different formulations of premixed analogue (mixed biphasic insulin aspart [BIAsp]), BIAsp 30 (30 % soluble insulin aspart [IAsp] and 70 % protaminated IAsp) and BIAsp 70 (70 % soluble IAsp and 30 % protaminated IAsp), in patients with type 1 diabetes using a 12-hour euglycaemic clamp technique. Methods: In this randomised, double-blind, two-period crossover trial, 27 patients with type 1 diabetes received 7 days of treatment with BIAsp 30 three times daily (TID) and 7 days of treatment with BIAsp 70 TID, with a 2 - 6 week washout period between treatment periods. At the start (day 1) and end (day 8) of each treatment period, 12-hour serum IAsp profiles and glucose infusion rate (GIR) profiles were determined during an overnight euglycaemic clamp following subcutaneous (sc) administration of a single 0.3 U/kg dose of trial insulin. All pharmacokinetic and pharmacodynamic endpoints were derived from individual serum IAsp and GIR profiles. Results: The larger fraction of soluble IAsp in BIAsp 70 compared with BIAsp 30 resulted in greater metabolic effect during the initial post-dosing phase (0 - 6 hours) and decreased activity during the late phase (6 - 12 hours). On day 8, AUC_{GIR 0 - 6 hours} was 16 % greater for BIAsp 70 than for BIAsp 30 (p = 0.016) and AUC_{GIR 6 - 12 hours} was 90 % (p < 0.001) greater for BIAsp 30 relative to BIAsp 70, reflecting the increased proportion of intermediate-acting (protamine co-crystallised) IAsp in BIAsp 30. Overall metabolic effect (AUC_{GIR 0 - 12 hours}) was similar for both insulin formulations on day 8 (Ratio, BIAsp 30:BIAsp 70 = 1.04, p = 0.538). Likewise, the larger fraction of soluble IAsp in BIAsp 70 compared with BIAsp 30 resulted in greater exposure to IAsp during the initial post-dosing phase (0 - 6 hours) and a smaller exposure to IAsp during the late phase (6 - 12 hours). On day 8, AUC_{IAsp 0 - 6 hours} was 59 % (p < 0.001) greater for BIAsp 70 than for BIAsp 30, and AUC_{IAsp 6 - 12 hours} was 61 % (p < 0.001) greater for BIAsp 30 than for BIAsp 70, reflecting the increased proportion of intermediate-acting (protamine co-crystallised) IAsp in BIAsp 30. However, the overall IAsp exposure (AUC_{0 - 12 hours}) on day 8 was significantly greater for BIAsp 70 than for BIAsp 30 (Ratio, BIAsp 30:BIAsp 70 = 0.73, p < 0.001). The GIR profiles on day 8 were similar to those on day 1. Serum IAsp profiles on day 8 showed a slight increase compared with day 1. Conclusions: The different proportions of soluble and protaminated IAsp result in differences in the pharmacokinetic and pharmacodynamic properties of BIAsp 30 and BIAsp 70. The pharmacokinetic and pharmacodynamic differences observed may allow for flexibility and individualised treatment regimens in patients with diabetes, while maintaining a limited number of daily injections.

Key words

Pharmacokinetics - pharmacodynamics - premixed analogue

References

• 1 Bell D, Bode B, Clements R S. Premixed versus self-mixed insulin in the treatment of type 2 diabetes mellitus: a randomized trial.  Today's Ther Trends. 1991;  9 63-73
• 2 Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics.  Diabetes Care. 1984;  7 188-199
• 3 Boehm B, Home P, Behrend C, Kamp N M, Lindholm A. Premixed insulin aspart vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.  Diabet Med. 2002;  19 393-399
• 4 Brange J, Vølund A. Insulin analogues with improved pharmacokinetic profiles.  Adv Drug Del Rev. 1999;  35 307-335
• 5 Chen J W, Lauritzen T, Christiansen J J, Jensen L H, Clausen W HO, Christiansen J S. Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: a randomized double-blinded crossover study.  Diabet Med. 2005;  22 273-277
• 6 Christiansen J S, Vaz J A, Metelko Z, Bogoev M, Dedov I. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.  Diabetes Obes Metab. 2003;  5 446-454
• 7 Coscelli C, Calabrese G, Fedele D, Pisu E, Calderini C, Bistoni S, Lapolla A, Mauri M G, Rossi A, Zappella A. Use of premixed insulin among the elderly: reduction of errors in patient preparation of mixtures.  Diabetes Care. 1992;  15 1628-1630
• 8 Dashora U, Ashwell S, Hilberg C, Vaz J, Home P. Thrice daily treatment with high-ratio biphasic insulin aspart improves lunch-time postprandial glucose control compared with twice daily treatment with low-ratio biphasic human insulin in people with Type 2 diabetes.  Diabetes. 2004;  53 (Suppl 2) A473
• 9 Declaration of Helsinki . Recommendations guiding medical physicians in biomedical research involving human subjects.  JAMA. 1997;  277 925-926
• 10 Ejskjaer N, Rasmussen M, Kamp N, Lindholm A, Christiansen J S. Comparison of thrice daily “high” vs. “medium” premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes.  Diabetes Obes Metab. 2003;  5 438-445
• 11 Heinemann L, Heise T, Jorgensen L N, Starke A AR. Action profile of the rapid acting insulin analogue B28 Asp.  Diabetic Med. 1993;  10 535-539
• 12 Hermansen K, Colombo M, Storgaard H. Improved postprandial glycaemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.  Diabetes Care. 2002;  25 883-888
• 13 Hollander P. Premixed insulins: How do they compare with other insulin preparations?.  Postgrad Med. 1991;  89 52-61
• 14 Home P, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.  Eur J Clin Pharmacol. 1999;  55 199-203
• 15 Kang S, Creagh F M, Peters J R, Brange J, Volund A, Owens D R. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9; GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type 1 diabetic subjects.  Diabetes Care. 1991;  14 571-577
• 16 Lindholm A. New insulins in the treatment of diabetes mellitus.  Best Pract Res Clin Gastroenterol. 2002;  16 475-492
• 17 McSorley P T, Bell P M, Jacobsen L V, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study trial in adult people with type 2 diabetes.  Clin Ther. 2002;  24 530-539
• 18 Owens D R, Zinman B, Bolli G B. Insulins today and beyond.  Lancet. 2001;  358 739-746
• 19 Puxty J, Hunter D, Burr W. Accuracy of insulin injection in elderly patients.  Br Med J. 1983;  287 1762
• 20 Rang H P, Dale M M, Ritter J M. Drug Elimination and Pharmacokinetics. Pharmacology. 4th ed. London; Churchill Livingstone 1999
• 21 Raskin P, Rojas P, Hu P, Allen E. for the INITIATE Study Group . Comparison of twice daily biphasic insulin aspart 70/30 (NovoLog Mix® 70/30) with once-daily insulin glargine in patients with type 2 DM on oral antidiabetic agents.  Diabetes. 2004;  53 (Suppl 2) A143
• 22 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes and the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-986
• 23 The Diabetes and Complications Trial Research group . Hypoglycaemia in the Diabetes control and Complications Trial.  Diabetes. 1997;  46 271-286
• 24 Thivolet C, Clements M, Ligthelm R J, Tits J, Kinsley B, Friberg H H. High-mix regimen of biphasic insulin aspart improves glycaemic control in patients with diabetes.  Diabetologia. 2002;  45 (Suppl 2) A254
• 25 UK Prospective Diabetes Study Trial Group (UKPDS) . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853